Viveve Medical, Inc. (NASDAQ:VIVE) went up to recover about 35.73% since recording its record low price of $4.1. The stock experienced -5.57% slump, arriving at $5.09 on Oct. 16, 2017. During the day, the stock price traveled from $5.09 to $5.35. This company shares are 161.3% off its target price of $13.3 and the current market capitalization stands at $100.58M. The recent change has given its price a -10.24% deficit over SMA 50 and -54.39% deficit over its 52-week high. The stock witnessed -7.96% declines, -28.11% declines and -34.49% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found VIVE’s volatility during a week at 4.68% and during a month it has been found around 4.8%.Viveve Medical, Inc. (VIVE) Top Holders
Institutional investors currently hold around $69 million or 80.1% in VIVE stock. Look at its top three institutional owners. Stonepine Capital Management, Llc owns $20.75 million in Viveve Medical, Inc., which represents roughly 20.63% of the company’s market cap and approximately 30.07% of the institutional ownership. Similar statistics are true for the second largest owner, Hightower Advisors, Llc, which owns 1,723,751 shares of the stock are valued at $9.29 million. The third largest holder is Rtw Investments, Lp, which currently holds $6.68 million worth of this stock and that ownership represents nearly 6.64% of its market capitalization.Viveve Medical, Inc. 13F Filings
At the end of June reporting period, 43 institutional holders increased their position in Viveve Medical, Inc. (NASDAQ:VIVE) by some 3,003,720 shares, 14 decreased positions by 2,057,688 and 3 held positions by 7,691,149. That puts total institutional holdings at 12,752,557 shares, according to SEC filings. The stock grabbed 35 new institutional investments totaling 1,879,498 shares while 6 institutional investors sold out their entire positions totaling 648,548 shares.Viveve Medical, Inc. (NASDAQ:VIVE) Insider Trades
Multiple company employees have indulged in significant insider trading. Viveve Medical, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Durbin Scott has acquired 5,000 shares of Viveve Medical, Inc. (VIVE) in trading session dated Aug. 23, 2017. These shares are worth $26,250 and were traded at $5.25 each. The SEC filing shows that Atkinson James G. performed a purchase of 375,000 shares. The Director added these shares by way of transaction on Mar. 17, 2017. The company’s shares were assimilated at $4 per share worth to an investment of some $1,500,000 on account of Atkinson James G..
CEO, Scheller Patricia, purchased 12,500 common shares of Viveve Medical, Inc. (VIVE) in the open market. In a transaction dated Mar. 17, 2017, the shares were bought at an average price of $4, giving away a sum of $50,000. After this purchase, 45,164 common shares of VIVE are directly owned by the insider, with total stake valued at $229,885.
In the transaction dated Mar. 17, 2017, the great number of shares acquired came courtesy the Director; Janney Daniel added a total of 500,000 shares at an average price of $4, amounting to approximately $2,000,000. The insider now directly owns 1,385,009 shares worth $7,049,696.Viveve Medical, Inc. (VIVE) Analyst Guide
Several analysts have released their opinion on Viveve Medical, Inc. (NASDAQ:VIVE), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.2 average brokerage recommendation.